Andrea Corbacioglu

5.0k total citations · 2 hit papers
21 papers, 2.7k citations indexed

About

Andrea Corbacioglu is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Andrea Corbacioglu has authored 21 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 10 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Andrea Corbacioglu's work include Acute Myeloid Leukemia Research (21 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Andrea Corbacioglu is often cited by papers focused on Acute Myeloid Leukemia Research (21 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Andrea Corbacioglu collaborates with scholars based in Germany, United States and Netherlands. Andrea Corbacioglu's co-authors include Konstanze Döhner, Hartmut Döhner, Richard F. Schlenk, Lars Bullinger, Stefan Fröhling, Marianne Habdank, Arnold Ganser, Jürgen Krauter, Brigitte Schlegelberger and Daniela Späth and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Andrea Corbacioglu

21 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

2008 1.1k citations Richard F. Schlenk, Konstanze Döhner et al. New England Journal of Medicine profile →
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

2005 603 citations Konstanze Döhner, Richard F. Schlenk et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Corbacioglu Germany	9	2.4k	1.3k	863	708	365	21	2.7k
Marianne Habdank Germany	9	2.3k 1.0×	1.3k 1.1×	895 1.0×	612 0.9×	462 1.3×	17	2.7k
Fiona Oliver United Kingdom	5	2.2k 0.9×	1.2k 0.9×	490 0.6×	810 1.1×	142 0.4×	6	2.4k
Christine Terré France	20	1.6k 0.6×	770 0.6×	579 0.7×	448 0.6×	159 0.4×	59	1.9k
S Chatters United Kingdom	6	1.3k 0.5×	521 0.4×	382 0.4×	416 0.6×	150 0.4×	8	1.4k
Martin Jädersten Sweden	22	1.7k 0.7×	857 0.7×	795 0.9×	137 0.2×	205 0.6×	63	2.1k
Ya‐Zhen Qin China	23	1.5k 0.6×	503 0.4×	472 0.5×	639 0.9×	107 0.3×	153	1.9k
Olivier Nibourel France	19	1.1k 0.4×	757 0.6×	669 0.8×	258 0.4×	337 0.9×	55	1.6k
N Philippe France	13	1.1k 0.4×	545 0.4×	626 0.7×	226 0.3×	194 0.5×	33	1.5k
Joseph O. Moore United States	10	1.0k 0.4×	555 0.4×	368 0.4×	350 0.5×	100 0.3×	17	1.3k
Fen‐Yu Lee Taiwan	14	918 0.4×	578 0.5×	432 0.5×	174 0.2×	192 0.5×	20	1.2k

Countries citing papers authored by Andrea Corbacioglu

Since Specialization

Citations

This map shows the geographic impact of Andrea Corbacioglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Corbacioglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Corbacioglu more than expected).

Fields of papers citing papers by Andrea Corbacioglu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Corbacioglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Corbacioglu. The network helps show where Andrea Corbacioglu may publish in the future.

Co-authorship network of co-authors of Andrea Corbacioglu

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Corbacioglu. A scholar is included among the top collaborators of Andrea Corbacioglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Corbacioglu. Andrea Corbacioglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kapp‐Schwoerer, Silke, Sibylle Cocciardi, Anna Dolnik, et al.. (2015). Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). Blood. 126(23). 1381–1381. 1 indexed citations

Gaidzik, Verena I., Richard F. Schlenk, Peter Paschka, et al.. (2011). DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. Blood. 118(21). 415–415. 2 indexed citations

Gaidzik, Verena I., Lars Bullinger, Richard F. Schlenk, et al.. (2011). RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. Journal of Clinical Oncology. 29(10). 1364–1372. 328 indexed citations

Paschka, Peter, Richard F. Schlenk, Julia Herzig, et al.. (2011). ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. Blood. 118(21). 412–412. 3 indexed citations

Taskesen, Erdogan, Lars Bullinger, Andrea Corbacioglu, et al.. (2010). Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 117(8). 2469–2475. 262 indexed citations

Corbacioglu, Andrea, Claudia Scholl, Richard F. Schlenk, et al.. (2010). Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(23). 3724–3729. 107 indexed citations

Gaidzik, Verena I., Richard F. Schlenk, Annegret Becker, et al.. (2009). Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 113(19). 4505–4511. 124 indexed citations

Paschka, Peter, Juan Du, Richard F. Schlenk, et al.. (2009). Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. Blood. 114(22). 825–825. 3 indexed citations

Gaidzik, Verena I., Cailian Wang, Richard F. Schlenk, et al.. (2009). Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.. Blood. 114(22). 1600–1600. 2 indexed citations

10.

Paschka, Peter, Juan Du, Richard F. Schlenk, et al.. (2009). Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).. Blood. 114(22). 824–824. 3 indexed citations

11.

Schlenk, Richard F., Konstanze Döhner, Jürgen Krauter, et al.. (2008). Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine. 358(18). 1909–1918. 1103 indexed citations breakdown →

12.

Deneberg, Stefan, Michael Grövdal, Monika Jansson, et al.. (2008). Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.. Blood. 112(11). 3337–3337. 1 indexed citations

13.

Bullinger, Lars, Frank G. Rücker, Juan Du, et al.. (2007). Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood. 110(4). 1291–1300. 85 indexed citations

14.

Corbacioglu, Andrea, Stefan Fröhling, Karina Eiwen, et al.. (2007). CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.. Blood. 110(11). 363–363. 3 indexed citations

15.

Corbacioglu, Andrea, Stefan Fröhling, Peter Paschka, et al.. (2007). Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).. Blood. 110(11). 762–762. 2 indexed citations

16.

Schlenk, Richard F., Konstanze Döhner, Michael Kneba, et al.. (2007). The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.. Blood. 110(11). 297–297. 9 indexed citations

17.

Fröhling, Stefan, Andrea Corbacioglu, Richard F. Schlenk, Hartmut Döhner, & Konstanze Döhner. (2007). In Reply. Journal of Clinical Oncology. 25(17). 2494–2495. 1 indexed citations

18.

Schlenk, Richard F., Andrea Corbacioglu, Jürgen Krauter, et al.. (2006). Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. Blood. 108(11). 4–4. 14 indexed citations

19.

Du, Juan, Richard F. Schlenk, Andrea Corbacioglu, et al.. (2006). RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. Blood. 108(11). 2303–2303. 1 indexed citations

20.

Döhner, Konstanze, Richard F. Schlenk, Marianne Habdank, et al.. (2005). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 106(12). 3740–3746. 603 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact